Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Ernest Mario purchased 120,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 23rd. The shares were acquired at an average cost of $0.41 per share, with a total value of $49,200.00. Following the completion of the acquisition, the director now directly owns 630,724 shares in the company, valued at $258,596.84. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ernest Mario also recently made the following trade(s):

  • On Tuesday, September 13th, Ernest Mario purchased 100,000 shares of Tonix Pharmaceuticals Holding Corp. stock. The shares were acquired at an average cost of $0.79 per share, with a total value of $79,000.00.

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded up 0.1010% on Monday, reaching $0.3964. The company’s stock had a trading volume of 2,326,785 shares. The company’s market cap is $15.53 million. The firm has a 50 day moving average of $0.51 and a 200 day moving average of $1.59. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $0.35 and a 52-week high of $7.95.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.05. Analysts predict that Tonix Pharmaceuticals Holding Corp. will post ($1.59) earnings per share for the current year.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

ILLEGAL ACTIVITY WARNING: “Ernest Mario Purchases 120,000 Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/28/ernest-mario-purchases-120000-shares-of-tonix-pharmaceuticals-holding-corp-tnxp-stock.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Tonix Pharmaceuticals Holding Corp. by 1.5% in the second quarter. Vanguard Group Inc. now owns 707,065 shares of the company’s stock worth $1,407,000 after buying an additional 10,531 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter worth about $290,000. Sabby Management LLC raised its position in shares of Tonix Pharmaceuticals Holding Corp. by 52.0% in the second quarter. Sabby Management LLC now owns 585,914 shares of the company’s stock worth $1,166,000 after buying an additional 200,518 shares during the last quarter. Opaleye Management Inc. bought a new position in shares of Tonix Pharmaceuticals Holding Corp. during the second quarter worth about $1,592,000. Finally, Franklin Resources Inc. raised its position in shares of Tonix Pharmaceuticals Holding Corp. by 279.4% in the second quarter. Franklin Resources Inc. now owns 1,610,045 shares of the company’s stock worth $3,204,000 after buying an additional 1,185,664 shares during the last quarter. Institutional investors and hedge funds own 10.25% of the company’s stock.

TNXP has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $5.00 price target on shares of Tonix Pharmaceuticals Holding Corp. in a report on Wednesday, August 24th. Roth Capital cut Tonix Pharmaceuticals Holding Corp. from a “buy” rating to a “neutral” rating in a report on Wednesday, September 7th. Finally, Oppenheimer Holdings Inc. cut Tonix Pharmaceuticals Holding Corp. from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 7th.

5 Day Chart for NASDAQ:TNXP

Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.